WO2012124982A3 - Oral preparation having an enteric coating - Google Patents
Oral preparation having an enteric coating Download PDFInfo
- Publication number
- WO2012124982A3 WO2012124982A3 PCT/KR2012/001846 KR2012001846W WO2012124982A3 WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3 KR 2012001846 W KR2012001846 W KR 2012001846W WO 2012124982 A3 WO2012124982 A3 WO 2012124982A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral preparation
- enteric coating
- relates
- present
- zoledronic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an oral preparation containing zoledronic acid, which reduces enteric injuries and improves bioavailability. More particularly, the present invention relates to an oral preparation having an enteric coating, which comprises zoledronic acid and the pharmaceutically acceptable salts thereof, and which has a core, the pH level of which is 3.5 to 7.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0023362 | 2011-03-16 | ||
KR1020110023362A KR20120105738A (en) | 2011-03-16 | 2011-03-16 | An enteric-coated oral formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012124982A2 WO2012124982A2 (en) | 2012-09-20 |
WO2012124982A3 true WO2012124982A3 (en) | 2012-11-08 |
Family
ID=46831213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/001846 WO2012124982A2 (en) | 2011-03-16 | 2012-03-14 | Oral preparation having an enteric coating |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20120105738A (en) |
WO (1) | WO2012124982A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3362071A4 (en) * | 2015-09-18 | 2019-07-17 | Grünenthal GmbH | Crystallization method and bioavailability |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009785A1 (en) * | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
WO2000061111A1 (en) * | 1999-04-09 | 2000-10-19 | Astrazeneca Ab | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
WO2001032185A1 (en) * | 1999-11-02 | 2001-05-10 | Cipla Ltd. | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof |
US6676965B1 (en) * | 1999-10-20 | 2004-01-13 | U&I Pharmaceuticals Ltd. | Enteric coated formulation for bisphosphonic acids and salts thereof |
US20050260262A1 (en) * | 2004-05-24 | 2005-11-24 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
KR100631873B1 (en) * | 2004-07-30 | 2006-10-09 | 주식회사 유유 | Alendronic Acid Formulations with Enhanced Bioavailability |
US20070134319A1 (en) * | 2003-12-23 | 2007-06-14 | Novartis Ag | Pharmaceutical formulations of bisphosphonates |
-
2011
- 2011-03-16 KR KR1020110023362A patent/KR20120105738A/en not_active Application Discontinuation
-
2012
- 2012-03-14 WO PCT/KR2012/001846 patent/WO2012124982A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993009785A1 (en) * | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
WO2000061111A1 (en) * | 1999-04-09 | 2000-10-19 | Astrazeneca Ab | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
US6676965B1 (en) * | 1999-10-20 | 2004-01-13 | U&I Pharmaceuticals Ltd. | Enteric coated formulation for bisphosphonic acids and salts thereof |
WO2001032185A1 (en) * | 1999-11-02 | 2001-05-10 | Cipla Ltd. | A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof |
US20070134319A1 (en) * | 2003-12-23 | 2007-06-14 | Novartis Ag | Pharmaceutical formulations of bisphosphonates |
US20050260262A1 (en) * | 2004-05-24 | 2005-11-24 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
KR100631873B1 (en) * | 2004-07-30 | 2006-10-09 | 주식회사 유유 | Alendronic Acid Formulations with Enhanced Bioavailability |
Also Published As
Publication number | Publication date |
---|---|
KR20120105738A (en) | 2012-09-26 |
WO2012124982A2 (en) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009066326A3 (en) | Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts | |
WO2011012816A3 (en) | Pharmaceutical formulation | |
WO2012025944A3 (en) | Sitagliptin, salts and polymorphs thereof | |
WO2013082345A8 (en) | Aryl dihydropyridinones and piperidinones as mgat2 inhibitors | |
WO2014041565A3 (en) | Improved process for preparation of vilanterol and intermediates thereof | |
WO2011157721A3 (en) | Ivabradine-containing pharmaceutical composition | |
WO2012056458A3 (en) | Intermediate compounds and process for the preparation of fingolimod | |
WO2014064255A3 (en) | Capsules | |
HRP20181437T1 (en) | Method for the preparation of (3s,3s') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) | |
WO2009117381A3 (en) | Preparation of montelukast and its salts | |
ZA201107412B (en) | Methods for the preparation of [2-8,9-dioxo2,6-diazabicyclo[5.2.0]non-1(1)-en-2-yl)ethyl]phosphonic acid and precursors thereof | |
WO2011058525A3 (en) | Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b | |
WO2008049922A3 (en) | A new process for the preparation of montelukast | |
UA106386C2 (en) | Method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid | |
WO2012112841A3 (en) | [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation | |
WO2013017910A8 (en) | Extended release pharmaceutical compositions containing paliperidone | |
WO2012074830A3 (en) | Modified release tranexamic acid formulation | |
BRPI1012007A2 (en) | "method for the preparation of 2-keto carboxylic acid" | |
WO2012018791A3 (en) | Preparation of prasugrel hydrochloride | |
WO2012014052A3 (en) | Novel coated extended release pharmaceutical compositions containing paliperidone | |
WO2011136513A3 (en) | Bone-transplant or bone-filling composition comprising a dihydroxybenzoic acid derivative | |
WO2010132390A3 (en) | Method of decreasing ubiquitylated protein levels | |
IL225680A0 (en) | Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives | |
WO2012124982A3 (en) | Oral preparation having an enteric coating | |
WO2011018801A3 (en) | Solid oral dosage form of ziprasidone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12757638 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12757638 Country of ref document: EP Kind code of ref document: A2 |